Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer

Table 1 NGS-based methods applied in the detection of ctDNA in ovarian cancer

Technique	Targeted or nontargeted sequencing	DNA volume of plasma/blood	DNA isolation (Yes/NO)	Analytical sensitivity	Quantitative Results	Type of alterations detected	Ref.
AmpliSeq	Targeted sequencing	2 ml plasma 1-100 ng DNA	Yes	>2%	Yes	SNVs, indels	[35, 36]
Safe-SeqS	Targeted sequencing	3 ng DNA	Yes	0.1%	Yes	SNVs, indels	[37, 38]
TAm-Seq	Targeted sequencing	< 2 ml plasma	Yes	>2%	Yes	SNVs, indels	[39]
Capp-Seq	Targeted sequencing	7-32 ng DNA	Yes	0.02%	Yes	SNVs, indels	[40]
TEC-Seq	Targeted sequencing	5-250 ng of cfDNA	Yes	0.05-01%	Yes	SNVs, indels	[41]
WES	nontargeted sequencing	50 ng-1μg DNA	Yes	>1-3%	Yes	SNVs, indels; CNV, rearrangements	[42,43,44]
WGS	nontargeted sequencing	250 ng DNA	Yes	1%	Yes	SNVs, indels; CNV, rearrangements, chromosomal aberrations	[45, 46]

Analytical sensitivity: % mutant to wild-type abundance ratio; Safe-SeqS Safe-Sequencing System, AmpliSeq Amplicon sequencing, TAm-Seq Tagged-amplicon deep sequencing, CAPP-Seq Cancer Personalized Profiling by deep Sequencing, TEC-Seq Targeted error correction sequencing, CNV copy number variations, SNV single nucleotide variations, WES whole-exome sequencing, WGS whole-genome sequencing.

ISSN: 1477-7827